| 000 | 01717 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517101604.0 | ||
| 264 | 0 | _c20170629 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1538-8514 | ||
| 024 | 7 |
_a10.1158/1535-7163.MCT-16-0025 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPeh, Jessie | |
| 245 | 0 | 0 |
_aThe Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas. _h[electronic resource] |
| 260 |
_bMolecular cancer therapeutics _c08 2016 |
||
| 300 |
_a1859-69 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCaspase 3 _xmetabolism |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrazones _xpharmacology |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins B-raf _xgenetics |
| 650 | 0 | 4 |
_aSulfonamides _xpharmacology |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 650 | 0 | 4 | _aVemurafenib |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aFan, Timothy M | |
| 700 | 1 | _aWycislo, Kathryn L | |
| 700 | 1 | _aRoth, Howard S | |
| 700 | 1 | _aHergenrother, Paul J | |
| 773 | 0 |
_tMolecular cancer therapeutics _gvol. 15 _gno. 8 _gp. 1859-69 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-16-0025 _zAvailable from publisher's website |
| 999 |
_c26121030 _d26121030 |
||